Waterloo Capital L.P. Cuts Stake in Pfizer Inc. (NYSE:PFE)

Waterloo Capital L.P. trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 67.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,232 shares of the biopharmaceutical company's stock after selling 41,162 shares during the quarter. Waterloo Capital L.P.'s holdings in Pfizer were worth $566,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Gilbert & Cook Inc. grew its stake in Pfizer by 3.8% in the fourth quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company's stock valued at $738,000 after purchasing an additional 945 shares during the last quarter. Gryphon Financial Partners LLC raised its stake in shares of Pfizer by 43.7% during the 4th quarter. Gryphon Financial Partners LLC now owns 26,942 shares of the biopharmaceutical company's stock worth $861,000 after acquiring an additional 8,194 shares in the last quarter. Quest Partners LLC purchased a new stake in Pfizer during the fourth quarter valued at approximately $186,000. Aigen Investment Management LP acquired a new stake in Pfizer in the fourth quarter valued at approximately $867,000. Finally, InterOcean Capital Group LLC grew its holdings in Pfizer by 5.3% in the fourth quarter. InterOcean Capital Group LLC now owns 25,864 shares of the biopharmaceutical company's stock worth $745,000 after purchasing an additional 1,291 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the subject of several analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and set a $45.00 price objective on shares of Pfizer in a report on Monday. UBS Group boosted their price target on Pfizer from $30.00 to $31.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 31st. StockNews.com raised shares of Pfizer from a "hold" rating to a "buy" rating in a research report on Thursday, August 1st. Wells Fargo & Company boosted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 31st. Finally, Daiwa America raised shares of Pfizer from a "moderate buy" rating to a "strong-buy" rating in a report on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $34.54.

Pfizer Stock Performance

Pfizer stock traded down $0.08 during midday trading on Thursday, hitting $29.67. 22,632,941 shares of the company were exchanged, compared to its average volume of 37,849,121. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $34.11. The business has a fifty day simple moving average of $29.35 and a two-hundred day simple moving average of $28.20. The firm has a market capitalization of $168.13 billion, a PE ratio of -494.42, a price-to-earnings-growth ratio of 1.02 and a beta of 0.68.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same quarter last year, the business earned $0.67 earnings per share. The firm's revenue was up 2.1% on a year-over-year basis. On average, sell-side analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.66%. The ex-dividend date of this dividend was Friday, July 26th. Pfizer's dividend payout ratio (DPR) is presently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.